RTP Mobile Logo
Meet The Professors: Clinical Investigators Provide Their Perspectives on Real Cases of Metastatic Breast Cancer
Released August 2013

Proceedings from a CME symposium held at the 2013 ASCO Annual Meeting. Featuring perspectives from Drs Lisa A Carey, Joyce O’Shaughnessy, Hope S Rugo, Eric P Winer and Denise A Yardley. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer.

    Breast cancer remains the most frequently diagnosed cancer in women, and it is estimated that 234,580 new cases and approximately 40,000 attributable deaths will occur in the United States in 2013 alone. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease.

    The current clinical management of breast cancer is multidisciplinary and includes surgical resection of local disease with or without radiation therapy and the treatment of systemic disease (micro- or macroscopic) with cytotoxic chemotherapy, endocrine therapy, biologic therapy or combinations of these agents. In addition, diagnosis may now include description of a molecular subtype, derived from either gene microarray analysis or simply immunohistochemical cellular receptor expression profiles. By providing access to the latest research developments and expert perspectives, these proceedings from a case-based CME symposium held at the 2013 ASCO Annual Meeting aim to assist medical oncologists, breast surgeons and other healthcare providers as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.


    • Employ case-based interactive learning to effectively adopt evidence-based therapeutic approaches for patients with metastatic breast cancer.
    • Implement a clinical plan for the management of advanced HER2-positive breast cancer, incorporating existing and recently approved targeted treatments.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for advanced ER-positive, pre- and postmenopausal breast cancer.
    • Demonstrate knowledge of emerging research to support alternative or novel chemotherapeutic regimens in the metastatic setting, and integrate these findings into best-practice disease management strategies.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component. Tthe participant should watch the video.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Lisa A Carey, MD
    Richardson and Marilyn Jacobs Preyer Distinguished
    Professor for Breast Cancer Research
    Chief, Division of Hematology and Oncology
    Physician-in-Chief, North Carolina Cancer Hospital
    Associate Director for Clinical Research
    Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

    Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi.

    Joyce O’Shaughnessy, MD
    Co-Director, Breast Cancer Research Program
    Baylor-Charles A Sammons Cancer Center
    Texas Oncology
    US Oncology
    Dallas, Texas

    Advisory Committee: Genentech BioOncology; Consulting Agreements: Arno Therapeutics Inc, Eisai Inc, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc, Sanofi.

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Agensys Inc, a subsidiary of Astellas Pharma US, Amgen Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MacroGenics Inc, Merck, Novartis Pharmaceuticals Corporation, Plexxikon Inc; Speakers Bureau: Genomic Health Inc.

    Eric P Winer, MD
    Thompson Chair in Breast Cancer Research
    Chief, Division of Women’s Cancers
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Contracted Research: Genentech BioOncology.

    Denise A Yardley, MD
    Senior Investigator, Breast Cancer Research
    Sarah Cannon Research Institute
    Tennessee Oncology, PLLC
    Nashville, Tennessee

    Advisory Committee: Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly USA LLC, Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Novartis Pharmaceuticals Corporation.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Lowell L Hart, MD
    Scientific Director of Clinical Research
    Director, Drug Development Program
    Florida Cancer Specialists
    Fort Myers, Florida

    Speakers Bureau: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    Robert A Moss, MD
    President, Medical Oncology Association of Southern California
    Private Practice
    Fountain Valley, California

    Contracted Research: Alexion Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Dendreon Corporation, Generon Corporation Ltd, Millennium: The Takeda Oncology Company, Pfizer Inc, Tesaro; Speakers Bureau: Dendreon Corporation, Genomic Health Inc, Novartis Pharmaceuticals Corporation.

    Estelamari Rodriguez, MD, MPH
    Medical Oncologist
    Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida

    Advisory Committee: Novartis Pharmaceuticals Corporation; Speakers Bureau: Roche Laboratories Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc and Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2013
    Expiration date: August 2014

Acknowledge and close

Watch video
(WiFi is recommended for best performance):